106 related articles for article (PubMed ID: 15963078)
1. Effect of hepatitis C infection on tacrolimus doses and blood levels in liver transplantation recipients.
Trotter JF; Osborne JC; Heller M; Christians U
Aliment Pharmacol Ther; 2005 Jul; 22(1):37-44. PubMed ID: 15963078
[TBL] [Abstract][Full Text] [Related]
2. Living donor liver transplant recipients achieve relatively higher immunosuppressant blood levels than cadaveric recipients.
Trotter JF; Stolpman N; Wachs M; Bak T; Kugelmas M; Kam I; Everson GT
Liver Transpl; 2002 Mar; 8(3):212-8. PubMed ID: 11910565
[TBL] [Abstract][Full Text] [Related]
3. Tacrolimus dosing requirements and concentrations in adult living donor liver transplant recipients.
Taber DJ; Dupuis RE; Fann AL; Andreoni KA; Gerber DA; Fair JH; Johnson MW; Shrestha R
Liver Transpl; 2002 Mar; 8(3):219-23. PubMed ID: 11910566
[TBL] [Abstract][Full Text] [Related]
4. 12-month follow-up analysis of a multicenter, randomized, prospective trial in de novo liver transplant recipients (LIS2T) comparing cyclosporine microemulsion (C2 monitoring) and tacrolimus.
Levy G; Grazi GL; Sanjuan F; Wu Y; Mühlbacher F; Samuel D; Friman S; Jones R; Cantisani G; Villamil F; Cillo U; Clavien PA; Klintmalm G; Otto G; Pollard S; McCormick PA
Liver Transpl; 2006 Oct; 12(10):1464-72. PubMed ID: 17004259
[TBL] [Abstract][Full Text] [Related]
5. Higher initial tacrolimus blood levels and concentration-dose ratios in kidney transplant recipients who develop diabetes mellitus.
Rodrigo E; de Cos MA; Fernández-Fresnedo G; Sánchez B; Ruiz JC; Piñera C; Palomar R; Cotorruelo JG; Gómez-Alamillo C; de Castro SS; de Francisco AL; Arias M
Transplant Proc; 2005 Nov; 37(9):3819-20. PubMed ID: 16386549
[TBL] [Abstract][Full Text] [Related]
6. Effect of calcineurin inhibitors on survival and histologic disease severity in HCV-infected liver transplant recipients.
Berenguer M; Aguilera V; Prieto M; San Juan F; Rayón JM; Benlloch S; Berenguer J
Liver Transpl; 2006 May; 12(5):762-7. PubMed ID: 16528713
[TBL] [Abstract][Full Text] [Related]
7. Survival and hepatitis C virus recurrence after liver transplantation in HIV- and hepatitis C virus-coinfected patients: experience in a single center.
Testillano M; Fernandez JR; Suarez MJ; Gastaca M; Bustamante J; Pijoan JI; Montejo M; Valdivieso A; Ruiz P; Gonzalez J; Ortiz de Urbina J
Transplant Proc; 2009 Apr; 41(3):1041-3. PubMed ID: 19376421
[TBL] [Abstract][Full Text] [Related]
8. A prospective randomized trial comparing tacrolimus and steroids with tacrolimus monotherapy in liver transplantation: the impact on recurrence of hepatitis C.
Margarit C; Bilbao I; Castells L; Lopez I; Pou L; Allende E; Escartin A
Transpl Int; 2005 Dec; 18(12):1336-45. PubMed ID: 16297052
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of tacrolimus in living donor liver transplant and deceased donor liver transplant recipients.
Jain A; Venkataramanan R; Sharma R; Kwong T; Orloff M; Abt P; Kashyap R; Tsoulfas G; Batzold P; Williamson M; Bozorgzadeh A
Transplantation; 2008 Feb; 85(4):554-60. PubMed ID: 18347534
[TBL] [Abstract][Full Text] [Related]
10. Significant improvement in the outcome of HCV-infected transplant recipients by avoiding rapid steroid tapering and potent induction immunosuppression.
Berenguer M; Aguilera V; Prieto M; San Juan F; Rayón JM; Benlloch S; Berenguer J
J Hepatol; 2006 Apr; 44(4):717-22. PubMed ID: 16487616
[TBL] [Abstract][Full Text] [Related]
11. A prospective, multicenter study of once-daily extended-release tacrolimus in de novo liver transplant recipients.
Charco R; Caralt M; Lladó L; Valdivieso A; Fabregat J; Matarranz A; Gonzalez-Pinto I; Pardo F; Fábrega E; Bilbao I
Transplant Proc; 2011 Apr; 43(3):718-23. PubMed ID: 21486582
[TBL] [Abstract][Full Text] [Related]
12. Hepatitis C virus therapy, hepatocyte drug metabolism, and risk for acute cellular rejection.
Kugelmas M; Osgood MJ; Trotter JF; Bak T; Wachs M; Forman L; Kam I; Everson GT
Liver Transpl; 2003 Nov; 9(11):1159-65. PubMed ID: 14586876
[TBL] [Abstract][Full Text] [Related]
13. Influence of immunosuppression and effect of hepatitis C virus on new onset of diabetes mellitus in liver transplant recipients.
Sánchez-Pérez B; Aranda Narváez JM; Santoyo Santoyo J; Fernández-Aguilar JL; Suárez Muñoz MA; González-Sánchez AJ; Pérez Daga JA; Ramírez Plaza CP; Carrasco Campos J; Jiménez Mazure C; Becerra Ortíz R
Transplant Proc; 2008 Nov; 40(9):2994-6. PubMed ID: 19010171
[TBL] [Abstract][Full Text] [Related]
14. Hepatitis C virus recurrence after liver transplantation: influence of immunosuppressive regimens on viral load and liver histology.
Oton E; Barcena R; Castillo M; Barreales M; Blesa C; Moreno-Planas JM; Barrios C; Garrido A; Cuervas V
Transplant Proc; 2006 Oct; 38(8):2499-501. PubMed ID: 17097980
[TBL] [Abstract][Full Text] [Related]
15. Diabetes mellitus after living donor liver transplantation: data from mainland China.
Zhao J; Yan L; Li B; Zeng Y; Wen T; Zhao J; Wang W; Xu M; Yang J; Ma Y; Chen Z; Wu H; Wei Y
Transplant Proc; 2009 Jun; 41(5):1756-60. PubMed ID: 19545722
[TBL] [Abstract][Full Text] [Related]
16. Recurrent hepatitis C virus disease after liver transplantation and concurrent biliary tract complications: poor outcome.
Katz LH; Mor E; Brown M; Bar-Nathan N; Shaharabani E; Sulkes J; Pappo O; Tur-Kaspa R; Ben-Ari Z
Clin Transplant; 2006; 20(4):465-70. PubMed ID: 16842523
[TBL] [Abstract][Full Text] [Related]
17. An objective measure to identify pediatric liver transplant recipients at risk for late allograft rejection related to non-adherence.
Venkat VL; Nick TG; Wang Y; Bucuvalas JC
Pediatr Transplant; 2008 Feb; 12(1):67-72. PubMed ID: 18186891
[TBL] [Abstract][Full Text] [Related]
18. A randomized, prospective, pharmacoeconomic trial of neoral 2-hour postdose concentration monitoring versus tacrolimus trough concentration monitoring in de novo liver transplant recipients.
Shenoy S; Hardinger KL; Crippin J; Korenblat K; Lisker-Melman M; Lowell JA; Chapman W
Liver Transpl; 2008 Feb; 14(2):173-80. PubMed ID: 18236391
[TBL] [Abstract][Full Text] [Related]
19. Tacrolimus dose requirement in relation to donor and recipient ABCB1 and CYP3A5 gene polymorphisms in Chinese liver transplant patients.
Wei-lin W; Jing J; Shu-sen Z; Li-hua W; Ting-bo L; Song-feng Y; Sheng Y
Liver Transpl; 2006 May; 12(5):775-80. PubMed ID: 16628701
[TBL] [Abstract][Full Text] [Related]
20. Influence of immunosuppressive therapy on the natural history of genotype 3 hepatitis-E virus infection after organ transplantation.
Kamar N; Abravanel F; Selves J; Garrouste C; Esposito L; Lavayssière L; Cointault O; Ribes D; Cardeau I; Nogier MB; Mansuy JM; Muscari F; Peron JM; Izopet J; Rostaing L
Transplantation; 2010 Feb; 89(3):353-60. PubMed ID: 20145528
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
